LLY

1,009.78

+2.29%↑

JNJ

230.21

+1.07%↑

ABBV

213.46

+1.18%↑

UNH

393.26

+1.95%↑

AZN

185.37

+0.94%↑

LLY

1,009.78

+2.29%↑

JNJ

230.21

+1.07%↑

ABBV

213.46

+1.18%↑

UNH

393.26

+1.95%↑

AZN

185.37

+0.94%↑

LLY

1,009.78

+2.29%↑

JNJ

230.21

+1.07%↑

ABBV

213.46

+1.18%↑

UNH

393.26

+1.95%↑

AZN

185.37

+0.94%↑

LLY

1,009.78

+2.29%↑

JNJ

230.21

+1.07%↑

ABBV

213.46

+1.18%↑

UNH

393.26

+1.95%↑

AZN

185.37

+0.94%↑

LLY

1,009.78

+2.29%↑

JNJ

230.21

+1.07%↑

ABBV

213.46

+1.18%↑

UNH

393.26

+1.95%↑

AZN

185.37

+0.94%↑

Home・Listă Acțiuni・Heron Therapeutics Inc

Heron Therapeutics Inc

Deschisă

SectorSănătate

0.85 -1.16

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

0.84

Maxim

0.88

Indicatori cheie
By Trading Economics
Venit	-5.2M -8.1M
Vânzări	-5.9M 35M
EPS	-0.04
Marjă de profit	-23.367
Angajați	128
EBITDA	-4M -4.8M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+311.76% upside

Dividende
By Dow Jones
Următoarele câștiguri	7 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-49M 181M
Deschiderea anterioară	2.01
Închiderea anterioară	0.85

Sentimentul știrilor

By Acuity

67%

33%

298 / 345 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

2.0001 / 2.42 Suport & Rezistență

Heron Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 mai 2026, 23:10 UTC

Acțiuni populare

Stocks to Watch: Agilysys, XP

18 mai 2026, 18:44 UTC

Principalele dinamici ale pieței

Claritev Shares Recover After Comments About DOJ

18 mai 2026, 23:55 UTC

Câștiguri

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mai 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mai 2026, 22:31 UTC

Achiziții, Fuziuni, Preluări

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mai 2026, 22:30 UTC

Achiziții, Fuziuni, Preluări

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mai 2026, 22:30 UTC

Achiziții, Fuziuni, Preluări

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mai 2026, 22:25 UTC

Achiziții, Fuziuni, Preluări

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mai 2026, 22:24 UTC

Achiziții, Fuziuni, Preluări

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 mai 2026, 20:50 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Financial Services Roundup: Market Talk

18 mai 2026, 20:25 UTC

Câștiguri

Correct: XP 1Q Total Client Assets BRL1.53T

18 mai 2026, 20:23 UTC

Câștiguri

XP 1Q Total Client Assets BRL1.53B

18 mai 2026, 20:19 UTC

Câștiguri

XP 1Q Adj EPS BRL2.49 >XP

18 mai 2026, 20:19 UTC

Câștiguri

XP 1Q Rev BRL4.73B >XP

18 mai 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mai 2026, 19:00 UTC

Câștiguri

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mai 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mai 2026, 18:17 UTC

Market Talk

Achiziții, Fuziuni, Preluări

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mai 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mai 2026, 16:57 UTC

Achiziții, Fuziuni, Preluări

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mai 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18 mai 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mai 2026, 16:54 UTC

Achiziții, Fuziuni, Preluări

Vinci Doesn't Set Out Financial Details of Deal

18 mai 2026, 16:50 UTC

Achiziții, Fuziuni, Preluări

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mai 2026, 16:49 UTC

Achiziții, Fuziuni, Preluări

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mai 2026, 16:49 UTC

Achiziții, Fuziuni, Preluări

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mai 2026, 16:48 UTC

Achiziții, Fuziuni, Preluări

Vinci Buys Canada's Modern Group of Companies

Comparație

Modificare preț

Heron Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

311.76% sus

Prognoză pe 12 luni

Medie 3.5 USD 311.76%

Maxim 4 USD

Minim 3 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHeron Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 2 analiști care au acordat evaluări ale acțiunilor Heron Therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

2.0001 / 2.42Suport & Rezistență

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

298 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.